Global Tinnitus Therapeutics Report 2016: Pipeline Analysis of 7 Companies & 10 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Tinnitus - Pipeline Review, H2 2016" report to their offering.

Tinnitus pipeline therapeutics constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Tinnitus - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Tinnitus Overview
  3. Therapeutics Development
  4. Pipeline Products for Tinnitus - Overview
  5. Pipeline Products for Tinnitus - Comparative Analysis
  6. Tinnitus - Therapeutics under Development by Companies
  7. Tinnitus - Therapeutics under Investigation by Universities/Institutes
  8. Tinnitus Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Tinnitus - Products under Development by Companies
  13. Tinnitus - Products under Investigation by Universities/Institutes
  14. Tinnitus - Companies Involved in Therapeutics Development
  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co. KgaA
  • Otonomy, Inc.
  • SciFluor Life Sciences, LLC
  • Sound Pharmaceuticals, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/zkpr6t/tinnitus

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals